The disclosure is directed to a gene transfer vector which comprises (i) all or part of a viral genome and (ii) a suicide gene flanked by unique cloning sequences. The disclosure also is directed to a system for producing an adenoviral vector comprising a destination vector comprising (i) all or part of an adenoviral genome and (ii) a suicide gene flanked by unique cloning sequences; a transgene flanked by unique cloning sequences; and (c) reagents for Gibson DNA Assembly (GDA). A method of producing an adenoviral vector using the aforementioned system also is provided.

The present invention relates to a method for preparing a composition comprising a viral vector, the method comprising the steps of a) providing viral vectors, (b) providing a solution comprising at least one sugar and at least three different excipients selected from hydrophilic and amphiphilic excipients, wherein the excipients are characterized by polar, aliphatic, aromatic, negatively charged, and/or positively charged functional groups, and wherein the solution is free or substantially free of Mg2+ or of any divalent cations and/or salts thereof; and (c) mixing the replication deficient viral vectors of step (a) with the solution of step (b). Furthermore, the invention relates to a composition obtained or obtainable by the method of the invention, and to a composition comprising a viral vector and the solution of step (b).

The present invention relates to an adenoviral vector or adeno-associated virus vector comprising a nucleotide sequence encoding a single cancer specific CD8+ T cell epitope, wherein the vector is capable of inducing an inflating memory CD8+ T cell response wherein said vector does not comprise a nucleic acid encoding further cancer specific T cell epitopes. It also relates to methods and uses of the vector.

The present invention relates to compositions and methods for monitoring viral synthesis inside a host cell. Compositions of the invention act as biosensors and can detect virus synthesized in a host cell in situ.

The present invention relates to compositions and methods for lysing cells and isolating and/or purifying adeno-associated virus particles or adenovirus particles using a detergent selected from the group of alkyldimethylamine oxides.

Methods for separating AAV empty capsids from mixtures of AAV vector particles and AAV empty capsids are described. The methods use column chromatography techniques and provide for commercially viable levels of recombinant AAV virions.

A Process for the Production of Adenovirus The present disclosure relates to a continuous process for the manufacture of an adenovirus wherein the process comprises the steps: A) continuously culturing, in a vessel, mammalian cells infected with the adenovirus in the presence of media suitable for supporting the cells such that the virus replicates, wherein the cells are capable of supporting viral replication, and B) isolating from the media the virus produced from step a) wherein the isolation of virus is not subsequent to a cell lysis step, wherein viable cells for virus infection and production are maintained in the vessel at a level suitable for replicating the virus for the period of continuous manufacture, wherein the process comprises at least one media change or addition and at least one cell change or addition. The disclosure also extends to viruses populations obtained or obtainable from the method.

Methods for separating AAV empty capsids from mixtures of AAV vector particles and AAV empty capsids are described. The methods use column chromatography techniques and provide for commercially viable levels of recombinant AAV virions.

Disclosed herein are methods of making vaults and packaging one or more passenger molecules in the internal cavities of the vault particles using cell-free techniques. Vaults according to the present invention and compositions comprising the vaults are free of cellular debris.

The present invention is based on the surprising discovery that the inclusion of an anionic polymer in the adenovirus formulation enhances long-term stability of the vector composition. An aqueous formulation comprising an adenovirus vector and at least one anionic polymer is provided, together with methods of the preparation of a storage stable adenovirus aqueous formulation.